Biogen (MEX:BIIB) Change In Receivables

: MXN-1,037 Mil (TTM As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

Biogen's change in receivables for the quarter that ended in Mar. 2023 was MXN2,069 Mil. It means Biogen's Accounts Receivable declined by MXN2,069 Mil from Dec. 2022 to Mar. 2023 .

Biogen's change in receivables for the fiscal year that ended in Dec. 2022 was MXN-4,336 Mil. It means Biogen's Accounts Receivable increased by MXN4,336 Mil from Dec. 2021 to Dec. 2022 .

Biogen's Accounts Receivable for the quarter that ended in Mar. 2023 was MXN36,558 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Biogen's Days Sales Outstanding for the three months ended in Mar. 2023 was 75.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Biogen's liquidation value for the three months ended in Mar. 2023 was MXN-65,042 Mil.

Biogen Change In Receivables Historical Data

The historical data trend for Biogen's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

-3,917.18

103.73

3,570.61

6,687.56

-4,335.91

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Receivables																-1,286.25	-529.10	-434.48	-2,142.61	2,069.27

Biogen Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,037 Mil.

Biogen (MEX:BIIB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Biogen's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	36558.305	/	44395.575	*	91
=	75.14

2. In Ben Graham's calculation of liquidation value, Biogen's accounts receivable are only considered to be worth 75% of book value:

Biogen's liquidation value for the quarter that ended in Mar. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	90869.432	-	194875.485	+	0.75 * 36558.305	+	0.5 * 23090.025
=	-65,042

Biogen Change In Receivables Related Terms

Thank you for viewing the detailed overview of Biogen's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (MEX:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BIIB:USA IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.